
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
Faculty
Douglas T. Johnston, DO, FAAAAI, FACAAI
Carolina Asthma & Allergy Center
Charlotte, NC
Faculty Disclosures
Douglas T. Johnston, DO, FAAAAI, FACAAI has disclosed the following relevant commercial financial
relationships or affiliations in the past 12 months.
BOARD MEMBERSHIP
Medical Advisory Board - APFED
CONSULTANCIES OR PAID ADVISORY BOARDS
Takeda
LECTURE FEES FOR SPEAKING AT THE INVITATION OF A COMMERCIAL SPONSOR
Takeda
about 5 years ago
Examining Unmet Needs in the Management of Eosinophilic Esophagitis





